Vertex Pharmaceuticals, Inc. (VRTX) Posts Smaller Q2 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. CSX
8. SAP
9. QGEN
10. ELV

Go back to Vertex Pharmaceuticals, Inc. (VRTX) Posts Smaller Q2 Loss

Vertex Pharma (VRTX) Receives EC Approval of KALYDECO in Certain Patients with CF

July 31, 2014 4:19 PM EDT

Vertex Pharma (Nasdaq: VRTX) announced that the European Commission has approved KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Todays approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations... More